Cervical squamous cell carcinoma remains a critical global health challenge, predominantly caused by persistent infection with high-risk HPV strains. Despite advancements in screening and vaccination, understanding the early molecular events leading to malignant transformation has been limited. In this context, the Xinjiang cohort’s scRNA-seq profiling has delineated keratinocyte subpopulations directly associated with HPV presence, marking a significant leap forward in characterizing the tumor microenvironment’s (TME) complexity.

Through rigorous sequencing of both tumor and adjacent normal cervical tissues from early-stage CESC patients, the investigators identified keratinocytes with high co-expression of PI3 and S100A7 as being disproportionately enriched within the tumor compartment. These PI3+S100A7+ keratinocytes exhibited transcriptional signatures denoting activated oncogenic pathways, including NF-κB and TNF signaling cascades, which are crucial mediators of inflammation and tumor progression. The pronounced expression of cytokine-receptor interaction genes within this subset underlines their role in orchestrating local immunological dynamics.

Spatial transcriptomic analysis and immunohistochemical validation revealed that these keratinocytes are frequently localized in proximity to CD163+ tumor-associated macrophages (TAMs). This juxtaposition suggests a bidirectional crosstalk wherein keratinocytes and macrophages co-activate signaling networks that facilitate tumor growth, promote invasion, and potentially aid immune evasion. These interactions encompass key chemokines and cytokines such as CCL2, CXCL8, and IL-10, which modulate macrophage recruitment and polarization, thus reshaping the immune milieu within the TME.

Intriguingly, the prognostic implications of PI3+S100A7+ keratinocyte infiltration were substantiated using The Cancer Genome Atlas (TCGA) data, wherein elevated presence correlated with significantly worse patient survival outcomes. Patients exhibiting high concurrent infiltration of both these keratinocytes and CD163+ macrophages showed the most pronounced decrease in overall survival, underscoring the clinical relevance of this cellular interplay.

Further dissecting stromal components, the study identified four fibroblast subtypes within tumor versus adjacent tissues. Among these, cancer-associated fibroblasts (CAFs) manifesting an inflammatory phenotype (C1 subtype) were predominantly expanded in tumor regions. These CAFs activated pathways that may synergize with keratinocyte-macrophage signaling to foster a pro-tumorigenic extracellular matrix and facilitate malignant progression, whereas undifferentiated fibroblasts (C3 subtype) mainly resided in non-cancerous tissues, indicating distinct stromal remodeling patterns.

Professor Ruozheng Wang, principal investigator, emphasized the dual significance of PI3 and S100A7, noting their marked overexpression in HPV-driven cervical cancer samples relative to normal controls. Immunohistochemistry not only confirmed co-localization but delineated a clearly defined keratinocyte subpopulation contributing uniquely to tumor biology. This finding advances the understanding of HPV-induced transcriptional reprogramming at the cellular level.

Moreover, the study underlines macrophages as key effectors modifying the TME through their enriched presence and potent crosstalk with keratinocytes mediated by pro-inflammatory and immunosuppressive factors, such as tumor necrosis factor (TNF) and interleukin-10 (IL-10). This milieu likely facilitates viral persistence and promotes early oncogenic transformation, posing challenges for immune clearance.

The intricate dialogue between HPV-infected keratinocytes and immune cells as revealed by this work highlights the dynamic remodeling of the tumor microenvironment, where viral oncogenesis intertwines with immune modulation and stromal reprogramming. This multifaceted interplay orchestrates an environment conducive to malignant initiation and progression, providing novel avenues for therapeutic intervention.

Importantly, this research advocates for targeting the identified signaling pathways and cell populations therapeutically. Inhibitors or immunomodulatory agents specifically designed to disrupt keratinocyte-macrophage communication or CAF activation could provide transformative strategies to halt or reverse early cervical cancer progression, marking a paradigm shift toward precision oncology.

This study not only enriches the molecular understanding of HPV-driven cervical carcinogenesis but also underscores the potential of single-cell technologies to unravel cellular heterogeneity and complex intercellular interactions within tumors. By pinpointing critical players like PI3+S100A7+ keratinocytes, it sets the groundwork for future diagnostics and targeted therapies demanding early-stage intervention.

In conclusion, the identification of this keratinocyte subtype reshaping the tumor microenvironment through crosstalk with immune and stromal elements opens new research frontiers. It paves the way for precise molecular targeting in early cervical squamous cell carcinoma and exemplifies how integrating high-resolution single-cell methodologies can revolutionize cancer biology and patient care.

Subject of Research: Cells
Article Title: Single-cell analysis identifies PI3+S100A7+ keratinocytes in early cervical squamous cell carcinoma with HPV infection
News Publication Date: 20-Oct-2025
Web References: Chinese Medical Journal article
References: DOI: 10.1097/CM9.0000000000003795
Image Credits: Professor Ruozheng Wang from The Affiliated Tumor Hospital of Xinjiang Medical University
Keywords: Cervical cancer, Oncology, Tumor microenvironments, Keratinocytes, Single cell sequencing, Immunology, Molecular biology, Gene expression, Biomarkers

Lipid metabolism has long been recognized as a crucial metabolic pathway exploited by cancer cells to support their rapid growth and invasive behavior. Among the many enzymes involved in this complex network, DHCR24 (24-dehydrocholesterol reductase) stands out due to its specific function in the cholesterol synthesis pathway. Cholesterol is essential not only for membrane structure but also for cellular signaling pathways that modulate tumor cell proliferation and survival. The study systematically examines how aberrant DHCR24 expression rewires lipid metabolism in cervical cancer, promoting features that underlie malignancy.

Utilizing comprehensive bioinformatics analyses, the researchers dissected the expression profile of DHCR24 in cervical carcinoma samples and correlated these data with clinical outcomes. The findings revealed a significant upregulation of DHCR24 in tumor tissues compared to normal counterparts. This overexpression strongly associated with histological subtypes of cervical cancer, as well as clinical factors such as body mass index (BMI) and patients’ responsiveness to therapy. These correlations underscore the potential of DHCR24 as both a biomarker and therapeutic target.

One of the most compelling aspects of the research lies in the development and validation of a prognostic nomogram that incorporates DHCR24 expression levels alongside tumor stage. This predictive model enables a more precise stratification of patients based on their risk, potentially guiding personalized treatment decisions. Importantly, survival analyses confirmed DHCR24 as an independent prognostic factor, elevating its clinical relevance beyond conventional staging systems.

Functionally, the study delved into the oncogenic roles of DHCR24 by employing SiHa cervical cancer cell lines. Through pharmacological inhibition using U18666A, a compound known to suppress DHCR24 activity, the researchers observed marked reductions in cellular proliferation, migration, and invasion capacities, which are hallmarks of cancer aggressiveness. These in vitro findings convincingly demonstrate that DHCR24 is not merely a bystander in tumor biology but actively orchestrates aggressive phenotypes.

Further biochemical assessments revealed that the inhibitory effects of U18666A were tightly linked to a dose-dependent decrease in intracellular cholesterol levels. This finding aligns with the hypothesis that DHCR24 promotes tumor progression by modulating cholesterol biosynthesis, which is vital for maintaining membrane integrity and facilitating oncogenic signaling pathways. Thus, interfering with this metabolic axis can thwart the tumor-supportive environment within cancer cells.

The research also explored the complex relationship between DHCR24 expression and the tumor immune microenvironment. Through computational analysis of public genomic datasets, the authors identified significant associations with tumor-infiltrating immune cells, suggesting that lipid metabolic reprogramming via DHCR24 influences immune modulation. This crosstalk between metabolism and immunity within the tumor milieu presents intriguing implications for immunotherapy strategies, which remain a frontier in cervical cancer treatment.

From a translational perspective, the study elevates DHCR24 from a molecular curiosity to a viable target for future therapeutic interventions. Given its dual role in promoting malignant progression and shaping immune landscapes, targeting DHCR24 could yield multifaceted clinical benefits, including sensitizing tumors to conventional therapies and overcoming immune resistance. Moreover, the robust diagnostic performance of DHCR24, as indicated by Receiver Operating Characteristic (ROC) analyses, bolsters its utility in early detection.

The insights gained here also echo broader trends in oncology, where metabolic reprogramming has emerged as a central theme in tumor biology. By illuminating how cholesterol biosynthesis intersects with cancer cell behavior and immune dynamics, this research contributes to a paradigm shift towards metabolism-centered therapeutic approaches. It also accentuates the necessity for integrative studies combining bioinformatics, molecular biology, and immunology to unravel the intricacies of cancer progression.

Given the gravity of cervical cancer morbidity and mortality worldwide, particularly in low-resource regions, these findings carry substantial public health implications. Early detection and personalized management guided by molecular markers like DHCR24 could significantly improve patient outcomes. The prospect of developing DHCR24 inhibitors or repurposing existing cholesterol-modulating agents warrants urgent exploration in preclinical and clinical settings.

Furthermore, the study’s methodological rigor, combining patient-derived data, in vitro functional assays, and computational analyses, sets a benchmark for future cancer metabolism research. By leveraging multiple layers of evidence, the investigators provide compelling proof that targeting metabolic enzymes such as DHCR24 is a feasible and promising strategy. This multidisciplinary approach underscores the complexity of cancer biology and the need for collaborative efforts across scientific domains.

The study also raises intriguing questions for ongoing research. For instance, the mechanisms by which DHCR24-mediated lipid changes influence specific immune cell populations within the tumor microenvironment remain to be dissected in detail. Such insights could unlock new biomarker panels and combination therapies that harness the immune system more effectively against cervical cancer.

Additionally, understanding whether DHCR24 expression levels vary across different stages and subtypes of cervical cancer may optimize its clinical application. Tailoring therapeutic interventions to the metabolic state of a tumor could minimize toxicity and maximize efficacy, aligning with the principles of precision oncology. Future studies involving larger patient cohorts and diverse populations will be critical in this regard.

In summary, this study delivers compelling evidence that DHCR24 is a key driver of lipid metabolic reprogramming, facilitating cervical cancer progression and modulating the immune landscape. Its heightened expression serves as a robust biomarker for prognosis and therapeutic responsiveness. Targeting DHCR24 offers a novel and promising strategy to halt tumor advancement and enhance patient survival rates, signaling a significant advancement in cervical cancer research.

As the scientific community continues to unravel cancer’s metabolic dependencies, enzymes like DHCR24 emerge as crucial nodes integrating tumor biology with immune regulation. This intricate balance paves the way for innovative therapies that disrupt the metabolic lifelines of cancer cells while empowering immune-mediated tumor eradication. The findings presented in this study are poised to inspire further investigations and accelerate the translation of metabolic targets into effective clinical treatments.

Ultimately, the convergence of lipid metabolism and immune modulation encapsulated in DHCR24 biology exemplifies the evolving landscape of cancer research—one that transcends traditional boundaries and embraces the complexity of tumor ecosystems. The future of cervical cancer management may well hinge on such interdisciplinary insights, bringing hope to millions affected by this devastating disease.

Subject of Research: The role of DHCR24 overexpression in lipid metabolic reprogramming and its effect on cervical cancer progression and tumor immune microenvironment.

Article Title: DHCR24 overexpression is involved in lipid metabolic reprogramming to drive cervical cancer malignant progression and is associated with immune microenvironment.

Article References:
Cheng, L., Xu, Y., Li, Z. et al. DHCR24 overexpression is involved in lipid metabolic reprogramming to drive cervical cancer malignant progression and is associated with immune microenvironment. BMC Cancer 25, 1291 (2025). https://doi.org/10.1186/s12885-025-14663-2

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14663-2

Cervical cancer remains a critical global health challenge, ranking as the fourth most prevalent cancer among females. Despite advances in screening and HPV vaccination programs, the disease continues to claim hundreds of thousands of lives annually, highlighting the urgent need for more refined diagnostic and treatment modalities. Traditional approaches, such as cytology and HPV testing, though valuable, fall short in offering precise prognostic insight or targeted therapies adaptable to tumor heterogeneity. The current study breaks new ground by integrating LLPS biology into the molecular landscape of cervical cancer.

Liquid-liquid phase separation is a biophysical phenomenon whereby specific proteins and nucleic acids condense into membraneless organelles, thereby orchestrating critical cellular processes. Aberrations in LLPS have been implicated in a variety of diseases, including neurodegeneration and cancer, yet their contribution to cervical carcinogenesis remained largely unexplored until now. Utilizing publicly available transcriptomic datasets from the GEO database, the researchers meticulously cataloged gene expression patterns linked to LLPS across six distinct cell types within cervical tumors.

The study identified a cohort of seven genes associated with LLPS that demonstrated prognostic relevance, serving as the backbone of a robust predictive model. This model stratified patients into high and low-risk groups based on their LLPS scores, with the former exhibiting significantly poorer survival outcomes. Notably, these divergent prognoses seem intricately connected to variations in the tumor’s immune microenvironment, where shifts in immune cell populations, such as CD8+ T cells, M0 macrophages, and regulatory T cells, may play critical roles in modulating tumor progression and immune evasion.

A particularly compelling finding of the study is the identification of PGK1 (phosphoglycerate kinase 1) as a core gene tightly linked to cervical cancer prognosis and immune infiltration dynamics. PGK1 is a glycolytic enzyme traditionally known for its role in energy metabolism; however, this research highlights its involvement far beyond metabolic regulation. Correlation analyses revealed that PGK1 expression is intricately connected to pathways governing lipid peroxidation, a process characterized by oxidative degradation of lipids that can influence cell fate decisions, including ferroptosis—a form of programmed cell death driven by iron-dependent accumulation of lipid peroxides.

To elucidate the functional impact of PGK1 downregulation, the researchers employed state-of-the-art immunofluorescence techniques and flow cytometry assays. These analyses demonstrated a marked increase in lipid peroxidation levels following PGK1 knockdown in cervical cancer cells, indicating that PGK1 acts as a suppressor of oxidative lipid damage in the tumor milieu. This insight provides a crucial link between metabolic rewiring and oxidative stress in cancer pathobiology, suggesting that targeting PGK1 could sensitize cancer cells to lethal lipid peroxidation.

Further validating the therapeutic potential of PGK1 inhibition, proliferation assays revealed that cervical cancer cell growth was significantly suppressed upon PGK1 downregulation. These findings were corroborated in vivo using a cell-derived xenograft (CDX) mouse model, where PGK1 knockdown led to reduced tumor growth and proliferation rates. This translational aspect of the study underscores PGK1’s candidacy as a viable molecular target for novel anti-cancer interventions aimed at exploiting the vulnerabilities of cancer metabolism and redox homeostasis.

Integral to the study was the comprehensive examination of the tumor immune microenvironment influenced by LLPS-related gene expression. Through immunohistochemistry staining, the researchers confirmed the association between key signature genes—including PDIA6, PGK1, ASPH, and FNDC3B—and immune infiltration patterns seen during tumorigenesis. These genes may contribute to shaping immunomodulatory landscapes, potentially affecting responses to immunotherapies and overall tumor aggressiveness.

The significance of the LLPS-related gene signature extends beyond prognostication; it holds promise for re-defining cervical cancer subtypes based on molecular and immunological attributes. This paradigm shift could facilitate precision oncology approaches, enabling clinicians to tailor treatments according to the unique molecular fingerprints of a patient’s tumor while considering their tumor’s immune contexture. Ultimately, such stratification could improve therapeutic responses and long-term outcomes for cervical cancer patients.

From a broader biomedical perspective, this study exemplifies the growing recognition that phase separation biology intersects profoundly with cancer research. The modulation of LLPS-associated proteins and pathways offers untapped therapeutic avenues, especially in cancers characterized by metabolic adaptation and immune suppression. By unraveling the role of PGK1 within this framework, the researchers contribute a crucial piece to the puzzle of how metabolic enzymes can moonlight as regulators of cellular stress and tumor behavior.

Additionally, the employment of integrative computational analyses combined with rigorous experimental validation signifies an exemplary approach to cancer research. By leveraging public genomic data and validating hypotheses using in vitro and in vivo models, the study sets a standard for future multi-omics investigations poised to decode the complexities of malignancies such as cervical cancer. This multi-layered methodology accelerates the translation from data-driven discoveries to clinical applications.

The confluence of lipid peroxidation mechanisms and cancer metabolism warrants further exploration, particularly in the context of emerging therapies like ferroptosis inducers, which could be potentiated by targeting PGK1. As lipid peroxidation contributes to cellular demise under oxidative stress, manipulating these pathways could selectively eliminate cancer cells while sparing normal tissue. Thus, PGK1 inhibitors or modulators may become part of combination regimens designed to overcome resistance to conventional therapies.

Finally, this comprehensive study reaffirms the necessity to look beyond traditional oncogenic drivers and to embrace novel biological phenomena such as LLPS in the fight against cancer. By connecting phase separation dynamics, metabolism, oxidative stress, and immune modulation, the findings open a multidimensional vista for innovative research and therapeutic development. As cervical cancer continues to burden millions globally, insights like these are essential for turning the tide against this formidable disease.

Subject of Research: Cervical cancer, LLPS-related gene signature, PGK1 function, lipid peroxidation, tumor proliferation, immune microenvironment.

Article Title: Downregulation of PGK1 promotes lipid peroxidation and suppresses proliferation in cervical cancer revealed by liquid-liquid phase separation-related gene signature.

Article References:
Zhang, B., Li, Z., Yang, Z. et al. Downregulation of PGK1 promotes lipid peroxidation and suppresses proliferation in cervical cancer revealed by liquid-liquid phase separation-related gene signature. BMC Cancer 25, 1269 (2025). https://doi.org/10.1186/s12885-025-14637-4

Image Credits: Scienmag.com

DOI: https://doi.org/10.1186/s12885-025-14637-4